PFM
NTLA icon

Privium Fund Management’s Intellia Therapeutics NTLA Stock Holding History

Privium Fund Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-58,709
Closed -$417K – 61
2025
Q1 		$417K Buy
58,709
+31,000
+112% +$313K 0.11% 46
2024
Q4 		$323K Buy
27,709
+15,409
+125% +$240K 0.07% 52
2024
Q3 		$253K Buy
+12,300
New +$284K 0.06% 69
2024
Q2 		– Sell
-8,905
Closed -$245K – 133
2024
Q1 		$245K Hold
8,905
– – 0.07% 80
2023
Q4 		$274K Hold
8,905
– – 0.08% 65
2023
Q3 		$282K Hold
8,905
– – 0.08% 65
2023
Q2 		$364K Hold
8,905
– – 0.1% 63
2023
Q1 		$332K Buy
8,905
+1,615
+22% +$63.3K 0.11% 58
2022
Q4 		$257K Buy
7,290
+2,000
+38% +$95.1K 0.1% 66
2022
Q3 		$292K Buy
5,290
+1,250
+31% +$77.5K 0.11% 80
2022
Q2 		$209K Buy
+4,040
New +$205K 0.07% 99

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Privium Fund Management's NTLA Position: Q2 2025 in Review

Privium Fund Management sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 58,709 shares — an estimated $417K sold.

Privium Fund Management first reported a position in NTLA in Q2 2022 and held it in 11 quarters. The position peaked at $417K in Q1 2025. 281 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • Privium Fund Management reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Privium Fund Management sold 58,709 Intellia Therapeutics shares in Q2 2025, an estimated $417K.
  • Privium Fund Management first reported a position in Intellia Therapeutics in Q2 2022 and held it in 11 quarters.
  • Privium Fund Management's Intellia Therapeutics position peaked at $417K in Q1 2025.
  • 281 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Privium Fund Management's 13F filing for Q2 2025, filed 30 Jul 2025.